Switch theme
Sign up to access all valuation multiples
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
2015
1.1K+
LTM Revenue $179M
LTM EBITDA -$69.4M
$2.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
InnoCare Pharma has a last 12-month revenue (LTM) of $179M and a last 12-month EBITDA of -$69.4M.
In the most recent fiscal year, InnoCare Pharma achieved revenue of $129M and an EBITDA of -$39.9M.
InnoCare Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See InnoCare Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $179M | XXX | $129M | XXX | XXX | XXX |
| Gross Profit | $156M | XXX | $111M | XXX | XXX | XXX |
| Gross Margin | 87% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | -$69.4M | XXX | -$39.9M | XXX | XXX | XXX |
| EBITDA Margin | -39% | XXX | -31% | XXX | XXX | XXX |
| EBIT | -$69.2M | XXX | -$67.1M | XXX | XXX | XXX |
| EBIT Margin | -39% | XXX | -52% | XXX | XXX | XXX |
| Net Profit | -$62.3M | XXX | -$56.2M | XXX | XXX | XXX |
| Net Margin | -35% | XXX | -44% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, InnoCare Pharma's stock price is HKD 14 (or $2).
InnoCare Pharma has current market cap of HKD 23.8B (or $3.0B), and EV of HKD 17.3B (or $2.2B).
See InnoCare Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.2B | $3.0B | XXX | XXX | XXX | XXX | $-0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, InnoCare Pharma has market cap of $3.0B and EV of $2.2B.
InnoCare Pharma's trades at 17.1x EV/Revenue multiple, and -55.2x EV/EBITDA.
Equity research analysts estimate InnoCare Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
InnoCare Pharma has a P/E ratio of -53.0x.
See valuation multiples for InnoCare Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV/Revenue | 13.4x | XXX | 17.1x | XXX | XXX | XXX |
| EV/EBITDA | -34.5x | XXX | -55.2x | XXX | XXX | XXX |
| EV/EBIT | -34.6x | XXX | -32.8x | XXX | XXX | XXX |
| EV/Gross Profit | 15.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -53.0x | XXX | -54.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -38.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInnoCare Pharma's last 12 month revenue growth is 38%
InnoCare Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
InnoCare Pharma's rule of 40 is -32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
InnoCare Pharma's rule of X is 55% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for InnoCare Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 38% | XXX | 42% | XXX | XXX | XXX |
| EBITDA Margin | -39% | XXX | -31% | XXX | XXX | XXX |
| EBITDA Growth | -20% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -32% | XXX | 7% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 55% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 26% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 81% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 138% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
InnoCare Pharma acquired XXX companies to date.
Last acquisition by InnoCare Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . InnoCare Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was InnoCare Pharma founded? | InnoCare Pharma was founded in 2015. |
| Where is InnoCare Pharma headquartered? | InnoCare Pharma is headquartered in Hong Kong. |
| How many employees does InnoCare Pharma have? | As of today, InnoCare Pharma has 1.1K+ employees. |
| Who is the CEO of InnoCare Pharma? | InnoCare Pharma's CEO is Dr. Jisong Cui, PhD. |
| Is InnoCare Pharma publicy listed? | Yes, InnoCare Pharma is a public company listed on HKG. |
| What is the stock symbol of InnoCare Pharma? | InnoCare Pharma trades under 09969 ticker. |
| When did InnoCare Pharma go public? | InnoCare Pharma went public in 2020. |
| Who are competitors of InnoCare Pharma? | Similar companies to InnoCare Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of InnoCare Pharma? | InnoCare Pharma's current market cap is $3.0B |
| What is the current revenue of InnoCare Pharma? | InnoCare Pharma's last 12 months revenue is $179M. |
| What is the current revenue growth of InnoCare Pharma? | InnoCare Pharma revenue growth (NTM/LTM) is 38%. |
| What is the current EV/Revenue multiple of InnoCare Pharma? | Current revenue multiple of InnoCare Pharma is 13.4x. |
| Is InnoCare Pharma profitable? | Yes, InnoCare Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of InnoCare Pharma? | InnoCare Pharma's last 12 months EBITDA is -$69.4M. |
| What is InnoCare Pharma's EBITDA margin? | InnoCare Pharma's last 12 months EBITDA margin is -39%. |
| What is the current EV/EBITDA multiple of InnoCare Pharma? | Current EBITDA multiple of InnoCare Pharma is -34.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
